drugset
drugset / Trial / NCT01847222

An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.

NCT01847222 ↗

Phase 1 Terminated 2 enrolled Prolong Pharmaceuticals
RandomizedParallel-groupSingle-blindBasic science

Summary

Safety assessment of SANGUINATE™ in Healthy Volunteers.

Timeline

Start
2013-05
Primary completion
2014-05
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject pegylated carboxyhemoglobin bovine Protein / enzyme biologic — —

Indications

No indication recorded.